ImmunoGen 과거 수익 실적

과거 기준 확인 0/6

ImmunoGen의 수입은 연평균 -5%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 19.1%의 비율로 증가했습니다. 매출은 연평균 23.3%의 비율로 증가해 왔습니다.

주요 정보

-5.0%

수익 성장률

12.9%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	23.3%
자기자본 수익률	-13.1%
순이익	-25.6%
최근 수익 업데이트	30 Sep 2023

최근 과거 실적 업데이트

Recent updates

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

Feb 09

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Jan 09

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Dec 22

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Oct 20

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

Aug 06

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Jul 20

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

May 03

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

Apr 18

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Feb 25

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

Jan 03

수익 및 비용 분석

ImmunoGen 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:IMGN 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Sep 23	288	-74	156
30 Jun 23	190	-180	152
31 Mar 23	121	-240	139
31 Dec 22	109	-223	116
30 Sep 22	96	-201	88
30 Jun 22	89	-161	64
31 Mar 22	92	-129	50
31 Dec 21	70	-139	44
30 Sep 21	128	-71	40
30 Jun 21	137	-56	40
31 Mar 21	135	-49	40
31 Dec 20	132	-44	39
30 Sep 20	91	-71	39
30 Jun 20	86	-70	38
31 Mar 20	87	-89	37
31 Dec 19	82	-104	38
30 Sep 19	51	-151	38
30 Jun 19	48	-176	38
31 Mar 19	42	-174	38
31 Dec 18	53	-169	37
30 Sep 18	79	-140	36
30 Jun 18	77	-150	36
31 Mar 18	107	-117	36
31 Dec 17	115	-96	34
30 Sep 17	90	-117	33
30 Jun 17	89	-105	35
31 Mar 17	57	-142	35
31 Dec 16	49	-157	39
30 Sep 16	53	-156	38
30 Jun 16	60	-145	34
31 Mar 16	65	-129	35
31 Dec 15	57	-119	31
30 Sep 15	87	-72	29
30 Jun 15	86	-61	28
31 Mar 15	79	-57	27
31 Dec 14	74	-73	26
30 Sep 14	56	-82	25
30 Jun 14	60	-71	24
31 Mar 14	58	-67	23
31 Dec 13	76	-31	22
30 Sep 13	49	-59	22
30 Jun 13	36	-73	21
31 Mar 13	35	-73	27

양질의 수익: IMGN 은(는) 현재 수익성이 없습니다.

이익 마진 증가: IMGN 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IMGN 은(는) 수익성이 없으며 지난 5년 동안 연간 5% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 IMGN 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: IMGN 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: IMGN 현재 수익성이 없기 때문에 마이너스 자본 수익률( -13.09% )을 갖습니다.

ImmunoGen 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

President notifies of intention to sell stock

Insider notifies of intention to sell stock

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Forecast breakeven date pushed back to 2024

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Insider notifies of intention to sell stock

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

Insider exercised options and sold US$3.0m worth of stock

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

New major risk - Share price stability

Price target increased by 10% to US$25.39

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold US$1.5m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Insider exercised options and sold US$1.9m worth of stock

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

Insider notifies of intention to sell stock

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

President recently sold US$17m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.0% to US$19.00

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Price target increased by 13% to US$16.20

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

Consensus revenue estimates increase by 80%

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Price target increased by 18% to US$14.10

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss, revenue downgraded

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기